欢迎访问《现代生物医学进展》编辑部！

目的：对弥漫大B 细胞淋巴瘤患者进行利妥昔单抗维持治疗(Maintenance Rituximab,MR)的安全性及疗效的研究和探讨。方法：38 例患者诱导治疗结束后根据患者及家属意见和经济条件分为MR 组和观察组。每组19 例。诱导治疗阶段两组患者均接受 6～8 个疗程R-CHOP(每3 周)或R-EPOCH 方案治疗。维持阶段，利妥昔单抗在诱导治疗完成后4-8 周开始，375mg／m2，每3 个月1 次共2 年(8 次)或直至疾病复发、进展、死亡。维持前均经影像学检查证实无复发。结果与结论：MR 对R-EPOCH 或R-CHOP 的诱导治疗后达到CRu/CR 初治DLBCL 病人，有很好的近期疗效，能提高其DFS 率，但OS 率无改善，而且其毒副反应小，可以耐受。

英文摘要:

Objective: To diffuse large B cell lymphoma of patients with rituxan safety maintenance treatment and curative effect is studied and discussed. Methods: 38 patients with induction after treatment according to the patient and family to opinions and economic conditions are divided into MR group and the observation group. Each group of 19 cases. The induction therapy stage two groups of patients will receive 6 ~ 8 a course R-CHOP (every three weeks) or R-EPOCH treatment plan. Maintain stage, rituxan in the induction therapy after the completion of the 4, 8 weeks, 375 mg/m2, once every 3 months of 2 years (eight) or until disease recurrence, progression, and death. Maintain both by imaging examination before shows no recurrence. Results and Conclusion: MR after R-EPOCH or R-CHOP induction therapy achieve after the CRu/CR DLBCL treated first patient, a very good short-term curative effect, can improve the DFS rate, but OS rate without improving, and its adverse reaction is small, can tolerate.

View Full Text View/Add Comment Download reader